A longevity peptide that selectively triggers "zombie cells" (old, damaged cells that refuse to die and cause inflammation) to self-destruct, while leaving healthy cells alone. One of the most precise tools available for clearing out these aging-related problem cells.
What to Expect
Week 1–2
Effects are at cellular level — senescent cell clearance beginning. No immediate subjective changes expected. Possible mild flu-like symptoms from apoptotic cell debris.
Week 3–6
Subtle improvements in tissue quality. Improved skin elasticity. Better joint comfort. Mild improvements in energy as senescent cell burden decreases.
Week 8+
Cumulative senolytic benefits — improved tissue function, reduced inflammatory burden from senescent cells. Anti-aging effects observable.
Common Side Effects
Scientific Overview
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. Cellular senescence involves p53 sequestration by FOXO4, preventing p53-mediated apoptosis. FOXO4-DRI competitively binds FOXO4, releasing p53 to trigger selective apoptosis in senescent cells while sparing healthy cells. This senolytic mechanism has demonstrated restoration of fur density, renal function, and fitness in aged mice. The D-retro-inverso modification provides protease resistance while maintaining the binding interface.
Dosing
5-10 mg subq every other day for 3 weeks. Rest for 2 months between cycles.
Practical Guide
Reconstitution
Mix vial with BAC water per research protocol. Dose based on body weight (mg/kg).
Storage
Refrigerate after reconstitution. Use within 7-14 days. Very expensive — accurate dosing critical.
Injection Sites
Subcutaneous injection. Short intensive protocols (3 consecutive days). Very expensive per dose.
Timing
Morning dosing during 3-day intensive courses. Space courses 2-4 weeks apart. Stay well-hydrated during treatment.
Food
No known food interactions.
Benefit Profile
Medical Considerations
Contraindications
- ✕Pregnancy/nursing
- ✕Active wound healing (kills senescent cells involved in healing)
- ✕Immunocompromised patients
- ✕Recent surgery
Drug Interactions
Recommended Monitoring
- →CBC and metabolic panel before and after treatment
- →Kidney and liver function (clearing cellular debris)
- →Monitor for systemic inflammation during treatment
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Cellular senescence in the aging and diseased kidney.
Cellular senescence as a therapeutic target to improve renal transplantation outcome.
[Molecular regulative mechanisms of aging and interventional effects of Chinese herbal medicine].
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells.
Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia.
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice.